Company: MDCXW
Filing Date: 2025-12-08
Form Type: 424B3
Source: 0001062993-25-017232
Chunk: 6

Company: Medicus Pharma Ltd.
Filing Date: 2025-12-08
Form: 424B3
Chunk 6
---
 thereof, any sales by the investor of Common Shares underlying the Existing Warrants or the New Warrants, the timing and effectiveness of the Registration Statement, whether the Shareholder Approval will be obtained, if required and any future sales of Common Shares under the SEPA to Yorkville. Forward-looking statements are often but not always, identified by the use of such terms as "may", "on track", "aim", "might", "will", "will likely result", "could," "designed," "would", "should", "estimate", "plan", "project", "forecast", "intend", "expect", "anticipate", "believe", "seek", "continue", "target", "potential" or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company's annual report on form 10-K for the year ended December 31, 2024 (the "Annual Report"), and in the Company's other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company's common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

<div align='center'>SIGNATURES</div>

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

​

| MEDICUS PHARMA LTD. |                                                |
| By:                 | /s/ Raza Bokhari                               |
| Name:               | Dr. Raza Bokhari                               |
| Title:              | Executive Chairman and Chief Executive Officer |

​

Dated: December 8,